In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

PPD signs new in-license deal with Lilly for dapoxetine

Executive Summary

Pharmaceutical Product Development (discovery and development services and compound partnering) will acquire from Lilly the patents for dapoxetine for development in the genitourinary field. PPD agrees to pay Lilly $65mm in cash up front, plus a royalty on net sales in excess of a set threshold (reported in industry news as 5% on sales over $800mm a year).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)
    • Reverse Licensing

Related Companies